NORI Protocol Case Reports

This case report highlights the medical history of a cancer patient who reached out to NORI in May 2012 for an alternative cancer treatment. This patient had previously undergone a complete thyroidectomy and lymph node dissection, but cancer had returned in additional lymph nodes located in the chest and lungs. With a thyroglobulin level of 13, the standard treatment options included more surgeries and radioactive iodine therapy. Opting for a natural approach, the patient initiated the NORI protocol, which at that time featured a predominantly fruit-based diet and high doses of sodium selenite. Remarkably, within 3 months, the thyroglobulin level dropped to a nearly undetectable range. This patient maintained an exceptionally low tumor marker level for over 4 years until a slight rise occurred. Upon reinitiating the NORI program, the levels were again reduced to near undetectable status. As of October 2019, this patient is in complete remission.

This patient contacted NORI in April 2018, suffering from extreme bone pain due to breast cancer metastasis to the spine and other skeletal structures. The CA15-3 tumor marker was nearly 1000, and scans clearly showed multiple lesions primarily in the bones. The NORI protocol, which is a part of innovative cancer treatment approaches, was immediately initiated and consisted of cycled methionine restriction along with two nutraceutical combinations. The first combination included sodium selenite, vitamin K3, and genipin (gardenia fruit extract), while the second combination featured grapeseed/pine bark extract, lutein, green tea extract, and eurycoma longifolia extract. Additionally, CBD was incorporated, and recently, boswellia serrata with ginger extract was added. Remarkably, the bone pain subsided within the first three months, and the CA15-3 level dropped to 250. The only conventional treatment utilized was an aromatase inhibitor. As of October 2019, this patient enjoys a high quality of life while continuing on the NORI program. Spot radiation has recently been applied to a lesion that has been causing some discomfort, but tumor markers remain stable and manageable, underscoring the effectiveness of the NORI protocol as demonstrated in various case reports.

This patient contacted NORI in December 2018 and was facing advanced CLL with a lymphocyte count of 360,000. The NORI protocol was initiated in January 2019, leading to a continuous decline in lymphocyte count, which is now approximately 50% of the peak value. Initially, the diet was not low-methionine due to weight concerns, but it has since transitioned to a cycled low-methionine diet while maintaining weight. The primary nutraceuticals involved in this cancer treatment include high doses of sodium selenite both orally and via IV, genipin (gardenia fruit extract), boswellia serrata/ginger extract, high doses of DHA (derived from algae oil omega-3), and CBD. Additionally, ozone therapy is being administered in a small portable infrared steam sauna. No conventional treatments have been undertaken. Expectations are that this patient will continue to see a decline in lymphocyte count along with improvements in red blood cell count and other hematological parameters. It's noteworthy that this patient is an integrative medical doctor who attempted self-treatment for 8 years without success. We are optimistic that the NORI program will lead to a complete remission of the CLL, as highlighted in several case reports.

This case report involves a patient diagnosed with Non-Hodgkin's Lymphoma (NHL) in May 2018, who did not receive any conventional cancer treatment after the diagnosis. The patient began the NORI protocol in September 2018. As of October 2019, there has been no progression of the enlarged lymph node in the neck and no signs of any other lymph node involvement, leading to the belief that the original lymph node is now benign. All blood markers are well within the normal range, and the oncologist advised the patient to continue the current approach. The protocol followed by this patient included a cycled methionine restricted diet, high doses of sodium selenite, berberine, genipin (gardenia fruit extract), and low-dose CBD. The patient reports feeling great, with plenty of energy and a stable, healthy weight. Sodium selenite is believed to be the primary element of the protocol that contributed to this positive response, as published human clinical trials indicate its effectiveness in treating NHL.

This patient contacted NORI in May 2018 and began the NORI protocol in June 2018 as part of an innovative cancer treatment approach. The patient's previous treatments included a total thyroidectomy and radioactive iodine. Upon starting the NORI protocol, there was a recurrence of thyroid cancer, with a tumor marker at 8.0 (Thyroglobulin) that was rising rapidly. No conventional treatments were administered during this time. The nutraceuticals included in this case report are high dose sodium selenite, genipin, berberine, and vitamin K3, along with a cycled methionine-restricted diet. After two months on the protocol, the Thyroglobulin level dropped to 5.9, and since then, the tumor marker has remained essentially stable for one year. Further reduction in the tumor marker is anticipated following modifications to the nutraceutical schedule. This patient is enjoying excellent health.

This recent case report (2020) highlights a stage IV papillary thyroid cancer patient who underwent a complete thyroidectomy, yet the cancer recurred. Upon initiation of the NORI protocol, the thyroglobulin tumor marker was 6.0, which remarkably dropped to 0.25 after just 2 months, demonstrating the effectiveness of the NORI protocol in cancer treatment. The patient adhered to a methionine restricted diet, with primary nutraceuticals including sodium selenite and vitamin E delta tocotrienol. Thyroid cancer has consistently shown excellent responses to the NORI protocol, likely due to its slow progressing nature. In contrast, conventional treatments for thyroid cancer, which typically involve multiple surgeries and radioactive iodine therapy, are largely ineffective, as there are no effective chemotherapeutic agents available.

In November 2019, a 53-year-old stage IV prostate cancer patient reached out to NORI with a PSA level of 395. NORI recommended hormonal therapy with Lupron along with the NORI protocol for cancer treatment. Remarkably, within one month, the patient's PSA dropped to 30, and a month later, it fell to a normal level of 1.7 (with normal being less than 4.0). This case report highlights that the patient underwent no surgery, chemotherapy, or radiation. As of September 2020, an MRI showed no signs of metastatic lesions, and the prostate appeared normal. The patient will continue to adhere to the NORI protocol alongside intermittent Lupron treatment. While Lupron effectively depletes testosterone and is a common approach for treating prostate cancer, its outcomes in this case were notably successful. Additionally, the patient followed a methionine-restricted diet plan of 7 days on and 7 days off, along with nutraceuticals like sodium selenite, vitamin K3, and Vitamin E delta tocotrienol.